CAMBRIDGE, Mass., April 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced two leadership promotions: John J. Keilty to vice president, information technology and informatics, and Joseph F. McPherson to vice president, facilities and operations. These appointments facilitate the advancement of Infinity's mission to discover, develop, and deliver to patients important new medicines for the treatment of cancer, and reflect Infinity's commitment to leadership development.
John J. Keilty, promoted to vice president, information technology and informatics, is a member of the Company's executive leadership team and has been a key figure in building Infinity's informatics and information technology development functions since joining the company as one of its earliest employees in early 2002. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity, Mr. Keilty was an early member of Millennium Pharmaceuticals where he had a diversity of responsibilities, including sequence analysis, genotyping, application development, and DNA sequencing. Mr. Keilty received his B.A. in biology from Clark University.
"John has worked tirelessly and has introduced tremendous innovation in the informatics arena to accelerate and support Infinity's mission to develop important new medicines to treat patients with cancer," said Julian Adams, Ph.D., president of research and development and chief scientific officer, Infinity. "John has also played a critical role in shaping and enhancing Infinity's core values and culture, and his enthusiasm and influence extends into all aspects of how Infinity operates."
Joseph F. McPherson, promoted to vice president, facilities and operations, joined Infinity at its inception in 2001 and has been instrumental in managing the company's expanding laboratories and office space, health and safety programs, and supply chain activities. Mr. McPherson joined Infinity with more than twenty years of laboratory and facility operations and management experience, and previously held positions at Applied Biotechnology, Inc., ImmuLogic Pharmaceutical, Inc., and Anadys Pharmaceuticals where he planned and managed the construction of the company's office/manufacturing space and relocations. Mr. McPherson received his B.S. in Biochemistry from the University of Massachusetts in Amherst.
"As one of Infinity's first employees, Joe has been instrumental in developing the fabric of our company," said Adelene Q. Perkins, president and chief business officer, Infinity. "The breadth and depth of Joe's expertise, combined with his energy and enthusiasm, has enabled him to make extraordinary contributions to the company's success. He is a key leader in executing on our growth strategy and I look forward to his future contributions."
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.